OXB — Oxford BioMedica Income Statement
0.000.00%
Last trade - 00:00
- £202.50m
- £212.27m
- £139.99m
- 15
- 32
- 19
- 10
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 66.8 | 64.1 | 87.7 | 143 | 140 |
Cost of Revenue | |||||
Gross Profit | 44 | 28.3 | 46.1 | 82.6 | 69.2 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 52.9 | 78.5 | 93.4 | 122 | 170 |
Operating Profit | 13.9 | -14.5 | -5.69 | 20.8 | -30.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 5.01 | -20.9 | -6.57 | 19.9 | -46 |
Provision for Income Taxes | |||||
Net Income After Taxes | 7.54 | -16.1 | -6.25 | 19 | -45.2 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 7.54 | -16.1 | -6.25 | 19 | -39.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 7.54 | -16.1 | -6.25 | 19 | -39.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.109 | -0.221 | -0.078 | 0.222 | -0.56 |
Dividends per Share |